Kazia Therapeutics Ltd - Company Profile
Powered by
All the data and insights you need on Kazia Therapeutics Ltd in one report.
- Save hours of research time and resources with
our up-to-date Kazia Therapeutics Ltd Strategy Report
- Understand Kazia Therapeutics Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kazia Therapeutics Ltd (Kazia) is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. The company’s product pipeline includes paxalisib (formerly GDC-0084), Cantrixil (TRX-E-002-1) and EVT801. Paxalisib is an inhibitor of PI3K /AKT /mTOR pathway to treat glioblastoma multiforme It is in phase II clinical trials. TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule that acts against cancer stem cells. Cantrixil is in phase I clinical trials for the treatment of ovarian cancer. EVT801 is a substance that blocks a cellular receptor called VEGFR3, which is responsible for the development of new blood and lymphatic vessels. The company has collaborations with various research institutes, hospitals, and universities including St Jude Children's Hospital, University of Newcastle, Dana Farber Cancer Institute and Memorial Sloan Kettering Cancer Centre to develop its pipeline. Kazia is headquartered in Sydney, New South Wales, Australia.
Kazia Therapeutics Ltd premium industry data and analytics
Products and Services
Products |
---|
Product Pipeline: |
Paxalisib (GDC-0084): |
Glioblastoma Multiforme |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Kazia Therapeutics Ltd | Amgen Inc | Biogen Inc | Gilead Sciences Ltd | Prescient Therapeutics Ltd |
---|---|---|---|---|---|
Headquarters | Australia | United States of America | United States of America | United Kingdom | Australia |
City | Sydney | Thousand Oaks | Cambridge | London | South Melbourne |
State/Province | New South Wales | California | Massachusetts | England | Victoria |
No. of Employees | 12 | 26,700 | 7,570 | 184 | 3 |
Entity Type | Private | Public | Public | Private | Public |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
John Friend, MD | Managing Director; Chief Executive Officer; Chairman - Interim | Executive Board | 2023 | - |
Mr Karen Krumeich | Chief Financial Officer | Senior Management | 2022 | - |
Anna Sandham | Secretary | Senior Management | 2023 | - |
Steven Coffey | Director | Non Executive Board | 2012 | - |
Bryce Carmine | Director | Non Executive Board | 2016 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward